Sponsor: Janssen Research and Development, LLC
Sponsor Study ID: MonumenTAL-6-64407564MMY3009
Study Title: A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
CTO #: 103914
NCT Number: NCT06208150
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Multiple Myeloma
Study Objectives: To compare the efficacy of either Tal-P or Tal-Tec with EPd or PVd.